Next Article in Journal
Developments and Challenges for mAb-Based Therapeutics
Previous Article in Journal
In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells
Previous Article in Special Issue
Characterization of a Phospho-Specific Antibody to the Fcε Receptor γ Chain, Reveals Differences in the Regulation of Syk and Akt Phosphorylation
Antibodies 2013, 2(3), 426-451; doi:10.3390/antib2030426
Review

Molecular Engineering of Therapeutic Cytokines

* ,  and
Received: 9 May 2013; in revised form: 13 June 2013 / Accepted: 13 June 2013 / Published: 3 July 2013
(This article belongs to the Special Issue Cytokine Growth Factor Antibodies in Immunotherapy)
View Full-Text   |   Download PDF [342 KB, uploaded 3 July 2013]   |   Browse Figure
Abstract: Over the past three decades, a large body of work has been directed at the development of therapeutic cytokines. Despite their central role in immune modulation, only a handful of cytokine therapeutics has achieved regulatory approval. One of the major challenges associated with the therapeutic use of cytokines relates to their short serum half-life and low bioavailability. High doses are required to overcome these problems, which often result in dose-limiting toxicities. Consequently, most cytokines require protein engineering approaches to reduce toxicity and increase half-life. For this purpose, PEGylation, fusion proteins, antibody complexes and mutagenesis have been utilized. Here, we summarize past, recent and emerging strategies in this area.
Keywords: immunotherapy; cytokines; protein engineering; immunocytokines; fusion proteins immunotherapy; cytokines; protein engineering; immunocytokines; fusion proteins
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Vazquez-Lombardi, R.; Roome, B.; Christ, D. Molecular Engineering of Therapeutic Cytokines. Antibodies 2013, 2, 426-451.

AMA Style

Vazquez-Lombardi R, Roome B, Christ D. Molecular Engineering of Therapeutic Cytokines. Antibodies. 2013; 2(3):426-451.

Chicago/Turabian Style

Vazquez-Lombardi, Rodrigo; Roome, Brendan; Christ, Daniel. 2013. "Molecular Engineering of Therapeutic Cytokines." Antibodies 2, no. 3: 426-451.


Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert